Reducing Brain Damage in Acute Stroke with a New Blood Substitute
Official title: Mitigation of Cerebral Infarct Growth in Acute Ischemic Stroke Using a Novel Blood Substitute
Funded at University of Chicago · NIH-11143286 · Data updated 2026-11-12
This project explores a new blood substitute to help protect brain cells and limit damage after an acute ischemic stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $596,070 |
| NIH project number | 5R01NS138410-02 |
| Project ID | NIH-11143286 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is ultimately intended for patients experiencing an acute ischemic stroke, especially those who might benefit from improved oxygen delivery and reduced brain cell death.
✕Less likely to help
Patients with other types of stroke, such as hemorrhagic stroke, or those without an acute ischemic event would not directly benefit from this specific treatment approach.
What this research studies
When an ischemic stroke happens, brain cells can die very quickly, and the amount of damage varies greatly among individuals. This project aims to test a new medication called Sanguinate®, which is designed to improve blood flow to affected areas and deliver oxygen to oxygen-deprived brain tissue. By boosting the body's natural ability to create new blood vessel connections and providing oxygen, this approach seeks to reduce the overall size of the stroke damage. It also hopes to lessen injury that can occur when blood flow is restored after a clot is removed.
Why it matters
Potential benefit: If successful, this new treatment could significantly reduce the amount of brain damage experienced by patients after an acute ischemic stroke, potentially leading to better recovery.
How similar studies have gone: Sanguinate® is an investigational agent, but its components and mechanisms of action are based on existing understanding of oxygen delivery and anti-inflammatory effects.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Carroll, Timothy J — University of Chicago
- Study coordinator: Carroll, Timothy J
Related research
Other NIH-funded projects on the same topics.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
Modeling Acute Ischemic Stroke to Improve Mechanical Thrombectomy
A research project is creating better computer models and animal studies to help remove clots more safely and effectively in people who have an acute ischemic stroke.
-
Nanoparticle-delivered tPA to overcome clot resistance in acute ischemic stroke
A Mayo Clinic team is testing a nanoparticle-delivered tPA approach to help dissolve clots more effectively in people with acute ischemic stroke due to large vessel blockage.
-
Engineered tissue regulatory T cells as a treatment for stroke
A new off-the-shelf cell therapy using engineered regulatory T cells could help people who have an ischemic stroke recover by reducing inflammation and promoting tissue repair.
-
Fast penumbral imaging to guide stroke treatment
Aims to develop quick MRI techniques to identify tissue at risk in acute ischemic stroke and help decide whether to use advanced clot-busting treatment.
-
Circadian factors shaping reperfusion success in acute stroke
This grant looks at how the body’s internal clock might influence how well stroke patients respond to clot-busting or clot-removal treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.